Chase Knickerbocker
Stock Analyst at Craig-Hallum
(4.35)
# 343
Out of 4,941 analysts
44
Total ratings
54.76%
Success rate
19.07%
Average return
Main Sectors:
Stocks Rated by Chase Knickerbocker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DMAC DiaMedica Therapeutics | Maintains: Buy | $8 → $11 | $4.58 | +140.17% | 1 | Jul 18, 2025 | |
| BFLY Butterfly Network | Initiates: Buy | $3 | $1.36 | +120.59% | 1 | Jul 1, 2025 | |
| INDV Indivior | Maintains: Buy | $15 → $22 | $22.29 | -1.30% | 4 | Jun 30, 2025 | |
| NRXS NeurAxis | Initiates: Buy | $7 | $2.43 | +188.07% | 1 | Jun 16, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $12 → $17 | $10.28 | +65.37% | 3 | Jun 9, 2025 | |
| FENC Fennec Pharmaceuticals | Maintains: Buy | $12 → $13 | $8.23 | +58.05% | 5 | May 14, 2025 | |
| ETON Eton Pharmaceuticals | Maintains: Buy | $26 → $28 | $17.05 | +64.22% | 6 | May 14, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $5 → $6.5 | $7.20 | -9.72% | 1 | Mar 7, 2025 | |
| MDWD MediWound | Initiates: Buy | $39 | $18.57 | +110.02% | 1 | Feb 28, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Buy | $10 → $8 | $0.84 | +856.59% | 4 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $21 | $10.51 | +99.81% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $6 | $4.04 | +48.51% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $12 | $4.66 | +157.51% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $3.23 | +209.60% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $65 | $33.74 | +92.65% | 3 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $7.04 | +70.45% | 2 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $8.21 | +21.80% | 1 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $23 | $12.79 | +79.83% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1 → $1.2 | $0.59 | +104.32% | 2 | Jul 11, 2023 |
DiaMedica Therapeutics
Jul 18, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $4.58
Upside: +140.17%
Butterfly Network
Jul 1, 2025
Initiates: Buy
Price Target: $3
Current: $1.36
Upside: +120.59%
Indivior
Jun 30, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $22.29
Upside: -1.30%
NeurAxis
Jun 16, 2025
Initiates: Buy
Price Target: $7
Current: $2.43
Upside: +188.07%
Phathom Pharmaceuticals
Jun 9, 2025
Maintains: Buy
Price Target: $12 → $17
Current: $10.28
Upside: +65.37%
Fennec Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $12 → $13
Current: $8.23
Upside: +58.05%
Eton Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $26 → $28
Current: $17.05
Upside: +64.22%
Xeris Biopharma Holdings
Mar 7, 2025
Maintains: Buy
Price Target: $5 → $6.5
Current: $7.20
Upside: -9.72%
MediWound
Feb 28, 2025
Initiates: Buy
Price Target: $39
Current: $18.57
Upside: +110.02%
Ironwood Pharmaceuticals
Jan 22, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $0.84
Upside: +856.59%
Jan 17, 2025
Maintains: Buy
Price Target: $18 → $21
Current: $10.51
Upside: +99.81%
Jan 17, 2025
Maintains: Buy
Price Target: $5 → $6
Current: $4.04
Upside: +48.51%
Nov 14, 2024
Maintains: Buy
Price Target: $16 → $12
Current: $4.66
Upside: +157.51%
Nov 4, 2024
Initiates: Buy
Price Target: $10
Current: $3.23
Upside: +209.60%
Oct 4, 2024
Maintains: Buy
Price Target: $45 → $65
Current: $33.74
Upside: +92.65%
Aug 1, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $7.04
Upside: +70.45%
Jul 11, 2024
Initiates: Buy
Price Target: $10
Current: $8.21
Upside: +21.80%
May 9, 2024
Maintains: Buy
Price Target: $22 → $23
Current: $12.79
Upside: +79.83%
Jul 11, 2023
Maintains: Buy
Price Target: $1 → $1.2
Current: $0.59
Upside: +104.32%